PY990106A - Composicion concentrada liquida, esencialmente no acuosa de sertralina - Google Patents

Composicion concentrada liquida, esencialmente no acuosa de sertralina

Info

Publication number
PY990106A
PY990106A PY199909900106A PY990106A PY990106A PY 990106 A PY990106 A PY 990106A PY 199909900106 A PY199909900106 A PY 199909900106A PY 990106 A PY990106 A PY 990106A PY 990106 A PY990106 A PY 990106A
Authority
PY
Paraguay
Prior art keywords
essentially non
sertraline
aqueous composition
concentrated liquid
pharmaceutically acceptable
Prior art date
Application number
PY199909900106A
Other languages
English (en)
Inventor
Ramchandra Ranade Gautam
Jane Harper Nancy
Mckowan Welch Willard
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22298286&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PY990106(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of PY990106A publication Critical patent/PY990106A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Obesity (AREA)
  • Addiction (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Child & Adolescent Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente invención proporciona una composición farmacéutica concentrada, líquida, esencialmente no acuosa de sabor aceptable y con estabilidad fisica/quimica a lo largo de la vida media del producto. Contiene sertralina o un sal farmacéuticamente,aceptables (ej. sal clorhidrato, sal mesilato) excipientes farmacéuticamente aceptables (ej. Etanol, glicerina) opcionalmente aromatizantes (ej. mentol) uno o mas conservantes (ej. BHT butilhidroxitolueno) tales como antioxidantes, quelantes de metales,y agentes antimicrobianos. Estas composiciones son utilizadas para tratar o prevenir afecciones provocadas por trastornos del sistema serotonérgico.
PY199909900106A 1998-10-13 1999-09-30 Composicion concentrada liquida, esencialmente no acuosa de sertralina PY990106A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10402498P 1998-10-13 1998-10-13

Publications (1)

Publication Number Publication Date
PY990106A true PY990106A (es) 2007-11-01

Family

ID=22298286

Family Applications (1)

Application Number Title Priority Date Filing Date
PY199909900106A PY990106A (es) 1998-10-13 1999-09-30 Composicion concentrada liquida, esencialmente no acuosa de sertralina

Country Status (46)

Country Link
EP (1) EP1121107B1 (es)
JP (1) JP3792514B2 (es)
KR (1) KR100417200B1 (es)
CN (1) CN1184962C (es)
AP (1) AP2001002119A0 (es)
AR (1) AR014082A1 (es)
AT (1) ATE254453T1 (es)
AU (1) AU766202B2 (es)
BG (1) BG65085B1 (es)
BR (1) BR9914418A (es)
CA (1) CA2346335C (es)
CO (1) CO5150213A1 (es)
CZ (1) CZ20011286A3 (es)
DE (1) DE69912978T2 (es)
DK (1) DK1121107T3 (es)
DZ (1) DZ2913A1 (es)
EA (1) EA003990B1 (es)
EE (1) EE04868B1 (es)
EG (1) EG23818A (es)
ES (1) ES2209490T3 (es)
GC (1) GC0000175A (es)
GE (1) GEP20032969B (es)
GT (1) GT199900171A (es)
HK (1) HK1040199B (es)
HR (1) HRP20010263B1 (es)
HU (1) HUP0104470A3 (es)
ID (1) ID29845A (es)
IS (1) IS2239B (es)
MA (1) MA26698A1 (es)
MY (1) MY122477A (es)
NO (1) NO20011829L (es)
NZ (1) NZ510756A (es)
OA (1) OA11662A (es)
PA (1) PA8483301A1 (es)
PE (1) PE20001108A1 (es)
PL (1) PL348119A1 (es)
PT (1) PT1121107E (es)
PY (1) PY990106A (es)
SK (1) SK4582001A3 (es)
TN (1) TNSN99190A1 (es)
TR (1) TR200101090T2 (es)
TW (1) TWI228043B (es)
UA (1) UA72743C2 (es)
WO (1) WO2000021521A2 (es)
YU (1) YU26401A (es)
ZA (1) ZA200102900B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0014166A (pt) 1999-09-03 2002-05-14 Lilly Co Eli Método de utilização de inibidores de reabsorção de serotonina seletivo de rápido ataque para tratamento de disfunção sexual
US20030086972A1 (en) * 2000-08-09 2003-05-08 Appel Leah E. Hydrogel-driven drug dosage form
WO2004065348A1 (en) * 2003-01-23 2004-08-05 Pfizer Products Inc. Pharmaceutically acceptable salts of sertraline and pharmaceutical compositions thereof
EP1626950A4 (en) * 2003-05-23 2007-05-23 Transform Pharmaceuticals Inc SERTRALINZUSAMMENSETZUNGEN
WO2005034910A1 (en) * 2003-10-08 2005-04-21 Ranbaxy Laboratories Limited Oral liquid pharmaceutical compositions of sertraline
WO2007052152A2 (en) * 2005-11-07 2007-05-10 Aurobindo Pharma Limited Sertraline oral concentrate
US20080268067A1 (en) 2007-03-09 2008-10-30 Llinas Rodolfo R Methods and Compositions for Treating Thalamocortical Dysrhythmia
CN109908354A (zh) * 2017-12-12 2019-06-21 万特制药(海南)有限公司 盐酸舍曲林口服浓缩液及其制备工艺
CN114225038A (zh) * 2021-06-02 2022-03-25 青海春天药用资源科技股份有限公司 酒精和凉味剂组合物在调节性功能、护血管、肝细胞再生、抗肿瘤、提高免疫及睡眠的用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4536518A (en) * 1979-11-01 1985-08-20 Pfizer Inc. Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine
ATE96999T1 (de) * 1989-08-30 1993-11-15 Pfizer Verwendung von sertralin zur behandlung von abhaengigkeiten von chemischen stoffen.
US4940731A (en) * 1989-08-30 1990-07-10 Pfizer Inc. Method of treating premature ejaculation using sertraline
US5130338A (en) * 1989-08-30 1992-07-14 Pfizer Inc. Method of treating chemical dependencies using sertraline
US4962128A (en) * 1989-11-02 1990-10-09 Pfizer Inc. Method of treating anxiety-related disorders using sertraline
CA2143070C (en) * 1994-02-22 2001-12-18 Pankaj Modi Oral controlled release liquid suspension pharmaceutical formulation
US5597826A (en) * 1994-09-14 1997-01-28 Pfizer Inc. Compositions containing sertraline and a 5-HT1D receptor agonist or antagonist
SE508372C2 (sv) * 1995-02-13 1998-09-28 Kjell Lindstroem Metod och utrustning för tillförsel eller aspiration av substanser inom gastrointestinalkanalen, avsedd för mätning av farmakokinetiska och fysikalisk-kemiska parametrar
ES2192217T3 (es) * 1995-07-17 2003-10-01 Pfizer Sertralina para el tratamiento de pacientes tras un infarto de miocardio.
ID24673A (id) * 1997-07-01 2000-07-27 Pfizer Prod Inc Bentuk-bentuk penakaran larutan sertralina dalam kapsul gelatin

Also Published As

Publication number Publication date
PT1121107E (pt) 2004-02-27
HRP20010263B1 (en) 2005-04-30
CZ20011286A3 (cs) 2001-09-12
DE69912978D1 (de) 2003-12-24
EP1121107B1 (en) 2003-11-19
HUP0104470A3 (en) 2003-12-29
NO20011829D0 (no) 2001-04-10
WO2000021521A3 (en) 2000-07-20
ID29845A (id) 2001-10-18
EE200100221A (et) 2002-08-15
AR014082A1 (es) 2001-01-31
EA200100285A1 (ru) 2001-10-22
BG105434A (bg) 2001-12-29
GT199900171A (es) 2001-03-28
EP1121107A2 (en) 2001-08-08
DZ2913A1 (fr) 2004-03-01
GEP20032969B (en) 2003-05-27
EG23818A (en) 2007-09-19
PE20001108A1 (es) 2000-10-26
TR200101090T2 (tr) 2001-12-21
MA26698A1 (fr) 2004-12-20
HK1040199B (zh) 2005-05-27
YU26401A (sh) 2005-07-19
JP2002527385A (ja) 2002-08-27
OA11662A (en) 2004-12-08
CA2346335C (en) 2006-04-18
TWI228043B (en) 2005-02-21
MY122477A (en) 2006-04-29
BG65085B1 (bg) 2007-02-28
ATE254453T1 (de) 2003-12-15
IS5906A (is) 2001-03-23
CN1184962C (zh) 2005-01-19
KR100417200B1 (ko) 2004-02-05
IS2239B (is) 2007-05-15
BR9914418A (pt) 2001-06-26
NO20011829L (no) 2001-06-05
CA2346335A1 (en) 2000-04-20
HRP20010263A2 (en) 2002-06-30
TNSN99190A1 (fr) 2005-11-10
KR20010080096A (ko) 2001-08-22
NZ510756A (en) 2003-05-30
JP3792514B2 (ja) 2006-07-05
AU5643699A (en) 2000-05-01
EA003990B1 (ru) 2003-12-25
EE04868B1 (et) 2007-08-15
AU766202B2 (en) 2003-10-09
PA8483301A1 (es) 2000-09-29
GC0000175A (en) 2006-03-29
UA72743C2 (en) 2005-04-15
HUP0104470A2 (en) 2002-08-28
DK1121107T3 (da) 2004-02-23
ES2209490T3 (es) 2004-06-16
DE69912978T2 (de) 2004-04-22
HK1040199A1 (en) 2002-05-31
SK4582001A3 (en) 2002-02-05
AP2001002119A0 (en) 2001-03-22
PL348119A1 (en) 2002-05-06
ZA200102900B (en) 2002-05-29
CN1323202A (zh) 2001-11-21
CO5150213A1 (es) 2002-04-29
WO2000021521A2 (en) 2000-04-20

Similar Documents

Publication Publication Date Title
MX2020010907A (es) Mejora de suministro de agentes activos lipofilicos a traves de la barrera hematoencefalica y metodos para tratar trastornos del sistema nervioso central.
WO2002042462A3 (en) Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
MY140576A (en) Cannabinoid active pharmaceutical ingredient for improved dosage forms
DE60121301D1 (de) Flibanserin zur Behandlung extrapyramidaler Bewegungsstörungen
CN106102732A (zh) 用于局部伤口治疗的制剂
IL152578A0 (en) Ortho-substituted anthranilic acid amides and their use as medicaments
PY990106A (es) Composicion concentrada liquida, esencialmente no acuosa de sertralina
JOP20210230A1 (ar) صياغات صيدلانية
RU2004103746A (ru) Фармацевтическая композиция для лечения интерстициального цистита
JP2024037972A (ja) 外用製剤
UA42719C2 (uk) Сполуки, композиції та способи, які інгібують протеази, для лікування та профілактики імуномедіаторних запальних хвороб
TR200200473T2 (tr) Rar selektif retinoid agonistleri.
UA92498C2 (ru) Каннабиноидно активный фармацевтический ингредиент для улучшенных дозированных форм
MY130445A (en) Novel formulations of alpha-2, 4-disulfophenyl-n-tert-butylnitrone
MY140025A (en) Stabilized topical formulations containing ketoprofen
AR040515A1 (es) Formula farmaceutica topica estabilizada con contenido de ketoprofeno
WO2019131654A1 (ja) 外用製剤
MXPA05008711A (es) Uso de r-10-hidroxi-10,11-dihidro-carbamazepina en dolor neuropatico.
WO2023150579A3 (en) Pharmaceutical formulations containing nalbuphine
MXPA04005033A (es) Composicion farmaceutica que comprende una combinacion de metformina y acido 4-oxobutanoico y el uso de la misma para el tratamiento contra diabetes.
SE0203817D0 (sv) New composition
ES2194899T3 (es) Composicion farmaceutica para administracion transdermica sistemica del principio activo morfina-6-glucuronido.
RU2008115908A (ru) Фармацевтическая композиция, содержащая гиалуронидазу и липосомы для наружного применения
WO1994016705A3 (en) Pharmaceutical composition containing 5-morpholinomethyl-3-(4-chlorobenzylideneamine)-2-oxazolidinone and its use for the treatment of cns disorders
WO2023028092A3 (en) Fluorinated empathogens